It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
ZeroHedge
That’s according to their preclinical research findings, published Aug. 1 in the Cell Chemical Biology journal.
Titled “Small Molecule Targeting of Transcription-Replication Conflict for Selective Chemotherapy,” the study found that a drug the researchers developed was able to selectively disrupt DNA replication and repair in cancer cells.
The drug is called AOH1996. It was named after Anna Olivia Healey, who was born in 1996 and died of a rare form of cancer called neuroblastoma when she was 9 years old.
Linda Malkas, a senior author of the new study based at the City of Hope, has been developing the drug over the past two decades.
City of Hope is a private, non-profit clinical research center, hospital, and graduate school in Duarte, California. It’s one of the largest cancer research and treatment organizations in the United States.
According to a press release from City of Hope, the AOH1996 “appears to annihilate all solid tumors.”
Now that research has demonstrated promising results in cell and animal models, the new drug is being tested in humans in a Phase 1 clinical trial, Ms. Malkas said in a statement.
originally posted by: lambs to lions
a reply to: worldstarcountry
What is RN3?